National Bank of Canada
APTO

National Bank of Canada’s Aptose Biosciences, Inc. APTO Stock Holding History

National Bank of Canada’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-93
Closed -$293 – 3274
2025
Q1 		$293 Buy
+93
New +$452 ﹤0.01% 2672
2024
Q3 		– Hold
0
– -$1 – 3112
2024
Q2 		– Hold
0
– – – 2688
2024
Q1 		– Hold
0
– – – 2717
2023
Q4 		– Hold
0
– – – 2677
2023
Q3 		– Hold
0
– – – 2763
2023
Q2 		– Hold
0
– – – 2712
2023
Q1 		– Hold
0
– – – 2674
2022
Q4 		– Hold
0
– – – 2739
2022
Q3 		– Hold
0
– – – 2957
2022
Q2 		– Hold
0
– – – 3060
2022
Q1 		– Hold
0
– – – 3082
2021
Q4 		– Hold
0
– – – 2856

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
CSC
Caldwell Sutter Capital Sausalito, California $246M AUM 23.62% 1-Year Est. Return

National Bank of Canada's APTO Position: Q2 2025 in Review

National Bank of Canada sold out of Aptose Biosciences, Inc. (APTO) in Q2 2025, closing a stake of 93 shares — an estimated $293 sold.

National Bank of Canada first reported a position in APTO in Q1 2025 and held it in 1 quarter. The position peaked at $293 in Q1 2025. 4 funds tracked by Wall St. Rank hold APTO as of Q2 2025.

  • National Bank of Canada reported no remaining Aptose Biosciences, Inc. position as of Q2 2025 after selling out during the quarter.
  • National Bank of Canada sold 93 Aptose Biosciences, Inc. shares in Q2 2025, an estimated $293.
  • National Bank of Canada first reported a position in Aptose Biosciences, Inc. in Q1 2025 and held it in 1 quarter.
  • National Bank of Canada's Aptose Biosciences, Inc. position peaked at $293 in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2025.

Based on National Bank of Canada's 13F filing for Q2 2025, filed 13 Aug 2025.